Table 2 Patients with malignant primary disease and oncological therapy in two hospices
From: Use of symptom-focused oncological cancer therapies in hospices: a retrospective analysis
Category and related p-valuea | Hospice 1 (H1) | Hospice 2 (H2) | Total | |||
|---|---|---|---|---|---|---|
Patients with oncological therapy in a hospice (p < 0.01) | 33 | 11% | 6 | 2% | 39 | 6% |
Age in years (average) | 69 (range: 44–93) | 68 (range: 56–87) | 68 (range: 44–93) | |||
Residence time in days | 67 (range: 4–440) | 44 (range: 4–100) | 55 (range: 4–440) | |||
Gender | ||||||
Male | 11 | 33% | 1 | 17% | 12 | 31% |
Female | 22 | 67% | 5 | 83% | 27 | 69% |
Malignant disease (primary diagnosis) | ||||||
Bronchial carcinomas | 5 | 15% | 1 | 17% | 6 | 15% |
Gastrointestinal cancers | 7 | 21% | 0 | 0% | 7 | 18% |
Gynecological cancers | 10 | 30% | 4 | 67% | 14 | 36% |
Brain cancers | 1 | 3% | 1 | 17% | 2 | 5% |
ENT tract cancers | 1 | 3% | 0 | 0% | 1 | 3% |
Other cancer (bone cancers, thyroid carcinomas, skin malignomas, cancer of unknown pirmary) | 0 | 0% | 0 | 0% | 0 | 0% |
Urological cancers | 6 | 18% | 0 | 0% | 6 | 15% |
Hematological systemic diseases | 3 | 9% | 0 | 0% | 3 | 8% |
Indication of oncological therapies (multiple indications per patient, where applicable) | 41 | 6 | 47 | |||
Dyspnea due to anaemia (p = 0.58) | 10 | 24% | 0 | 0% | 10 | 21% |
Diarrhea due to cancer disease (p = 1.00) | 2 | 5% | 0 | 0% | 2 | 4% |
Bone pain (p = 0.65) | 13 | 32% | 2 | 33% | 15 | 32% |
Meningeal cancer manifestation (p = 1.00) | 1 | 2% | 0 | 0% | 1 | 2% |
Continuation of ongoing anti-proliferative therapy (p = 0.01) | 0 | 0% | 2 | 33% | 2 | 4% |
Nausea/vomiting due to cancer disease (p = 1.00) | 1 | 2% | 0 | 0% | 1 | 2% |
Complications due to leukocytosis (p = 1.00) | 3 | 7% | 0 | 0% | 3 | 6% |
Pain therapy (p = 0.12) | 4 | 10% | 2 | 33% | 6 | 13% |
Other complications due to cancer disease (p = 1.00) | 3 | 7% | 0 | 0% | 3 | 6% |
Oncological therapy (multiple treatment, where applicable) | 41 | 6 | 47 | |||
Anti-hormonal therapy (p = 0.27) | 5 | 12% | 2 | 33% | 7 | 15% |
Targeted therapies (antibody therapy, tyrosine kinase inhibitors, somatostatin analogues; p = 0.44) | 4 | 10% | 2 | 33% | 6 | 13% |
Chemotherapy (p = 0.01) | 6 | 15% | 0 | 0% | 6 | 15% |
Radiotherapy (p = 0.01) | 6 | 15% | 0 | 0% | 6 | 13% |
Bisphosphonates (p = 0.02) | 10 | 24% | 2 | 33% | 12 | 26% |
Transfusions (p < 0.01) | 10 | 24% | 0 | 0% | 10 | 21% |
Clinical course | ||||||
Discharge | 2 | 6% | 1 | 17% | 3 | 8% |
Hospitalization | 1 | 3% | 1 | 17% | 2 | 5% |
For survival time see Fig. 2 | ||||||